• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

    8.130 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8
    Open 8.130
    Bid (Size) 8.160 (100)
    Ask (Size) 8.190 (100)
    Prev. Close 8.130
    Today's Range 8.130 - 8.130
    52wk Range 1.780 - 13.67
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    On Thursday, there are stocks with unusual volume. Let's take a look. ↗
    Let's have a look at the stocks with an unusual volume in today's session. 
    Via Chartmill

    Performance

    YTD
    -7.3%
    -7.3%
    1 Month
    -1.7%
    -1.7%
    3 Month
    +38.0%
    +38.0%
    6 Month
    +218.8%
    +218.8%
    1 Year
    +113.4%
    +113.4%

    More News

    Read More
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
    Via AB Newswire
    News headline image
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Which stocks are gapping on Monday? ↗
    Via Chartmill
    News headline image
    KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? ↗
    Via Stocktwits
    News headline image
    Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
    Via Benzinga
    News headline image
    Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
    From Kyverna Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Top movers in Wednesday's session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
    Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
    The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
    What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
    The current price of Kyverna Therapeutics, Inc. - Common Stock is 8.130
    When was Kyverna Therapeutics, Inc. - Common Stock last traded?
    The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 01/05/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.